These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19533640)

  • 1. Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful?
    Pichiecchio A; Poloni GU; Ravaglia S; Ponzio M; Germani G; Maranzana D; Costa A; Repetto A; Tavazzi E; Danesino C; Moglia A; Bastianello S
    Muscle Nerve; 2009 Jul; 40(1):122-5. PubMed ID: 19533640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
    Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
    Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT
    Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
    Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
    Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease.
    van Capelle CI; Winkel LP; Hagemans ML; Shapira SK; Arts WF; van Doorn PA; Hop WC; Reuser AJ; van der Ploeg AT
    Neuromuscul Disord; 2008 Jun; 18(6):447-52. PubMed ID: 18508267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early pathologic changes and responses to treatment in patients with later-onset Pompe disease.
    Chien YH; Lee NC; Huang PH; Lee WT; Thurberg BL; Hwu WL
    Pediatr Neurol; 2012 Mar; 46(3):168-71. PubMed ID: 22353292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited.
    Schoser BG; Müller-Höcker J; Horvath R; Gempel K; Pongratz D; Lochmüller H; Müller-Felber W
    Neuropathol Appl Neurobiol; 2007 Oct; 33(5):544-59. PubMed ID: 17573812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
    Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
    Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat?
    Laloui K; Wary C; Carlier RY; Hogrel JY; Caillaud C; Laforêt P
    Neurology; 2011 Aug; 77(6):594-5. PubMed ID: 21753173
    [No Abstract]   [Full Text] [Related]  

  • 13. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease.
    Drost MR; Schaart G; van Dijk P; van Capelle CI; van der Vusse GJ; Delhaas T; van der Ploeg AT; Reuser AJ
    Muscle Nerve; 2008 Feb; 37(2):251-5. PubMed ID: 17894362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response.
    Ravaglia S; Pichiecchio A; Ponzio M; Danesino C; Saeidi Garaghani K; Poloni GU; Toscano A; Moglia A; Carlucci A; Bini P; Ceroni M; Bastianello S
    J Inherit Metab Dis; 2010 Dec; 33(6):737-45. PubMed ID: 20844963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed or late-onset type II glycogenosis with globular inclusions.
    Sharma MC; Schultze C; von Moers A; Stoltenburg-Didinger G; Shin YS; Podskarbi T; Isenhardt K; Tews DS; Goebel HH
    Acta Neuropathol; 2005 Aug; 110(2):151-7. PubMed ID: 15986226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rat heart perfusion as model system for enzyme replacement therapy in glycogenosis type II.
    van der Ploeg AT; van der Kraaij AM; Willemsen R; Kroos MA; Loonen MC; Koster JF; Reuser AJ
    Pediatr Res; 1990 Oct; 28(4):344-7. PubMed ID: 2235132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mutation of the GAA gene in a Finnish late-onset Pompe disease patient: clinical phenotype and follow-up with enzyme replacement therapy.
    Korpela MP; Paetau A; Löfberg MI; Timonen MH; Lamminen AE; Kiuru-Enari SM
    Muscle Nerve; 2009 Jul; 40(1):143-8. PubMed ID: 19472353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.